Profile
Ian A. Critchley was Executive Director-Microbiology at Replidyne, Inc. from 2002 to 2008.
From 2008 to 2014, served as Vice President-Clinical Microbiology at Cerexa, Inc. Between 2015 and 2018, held the position of Vice President-Clinical Microbiology at Allergan UC.
Currently holds the title of Vice President-Clinical Microbiology at Spero Therapeutics, Inc. Education includes a doctorate from the University of Glasgow.
Former positions of Ian Critchley
| Companies | Position | End |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Corporate Officer/Principal | 2026-02-28 |
| ALLERGAN PLC | Corporate Officer/Principal | 2018-03-31 |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Corporate Officer/Principal | 2014-11-30 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Develops and commercializes novel antibiotics to treat infections caused by drug resistant bacteria | Corporate Officer/Principal | 2008-05-31 |
Training of Ian Critchley
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Develops and commercializes novel antibiotics to treat infections caused by drug resistant bacteria | Health Technology |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
University of Glasgow
University of Glasgow Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes pharmaceuticals, devices, biological, surgical & regenerative medicine products | Health Technology |
Spero Therapeutics, Inc.
Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
- Stock Market
- Insiders
- Ian Critchley
















